Celgene (BUE:CELG) EBITDA Margin %: 50.40% (As of Sep. 2019)


What is Celgene EBITDA Margin %?

Celgene BUE:CELG 10 EBITDA Margin % is 50.40% as of Sep. 2019. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Celgene's EBITDA for the three months ended in Sep. 2019 was ARS127,399.43 Mil. Celgene's Revenue for the three months ended in Sep. 2019 was ARS252,785.52 Mil. Therefore, Celgene's EBITDA margin for the quarter that ended in Sep. 2019 was 50.40%.

Celgene  (BUE:CELG) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Celgene EBITDA Margin % Related Terms

Celgene EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Celgene's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene EBITDA Margin % Chart

Celgene Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.45 29.56 30.07 40.81 40.63

Celgene Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.71 36.59 53.74 49.34 50.40

BUE:CELG vs GILD, BIIB, ACT: EBITDA Margin % Comparison

For the Drug Manufacturers - General subindustry, Celgene's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celgene EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celgene's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Celgene's EBITDA Margin % falls into.


Celgene EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Celgene's EBITDA Margin % for the fiscal year that ended in Dec. 2018 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2018 )/Revenue (A: Dec. 2018 )
=234072.652/576170.135
=40.63 %

Celgene's EBITDA Margin % for the quarter that ended in Sep. 2019 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2019 )/Revenue (Q: Sep. 2019 )
=127399.426/252785.516
=50.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 50.40% mean?
Celgene (BUE:CELG) has a EBITDA Margin % of 50.40% as of Sep. 2019. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Celgene and its competitors.
Is Celgene's EBITDA Margin % too high?
Celgene's current EBITDA Margin % is 50.40%. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Celgene's value of 50.40% is 302.7% above this industry median. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's EBITDA Margin % compare to GILD and BIIB?
Celgene's EBITDA Margin % of 50.40% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.52. Celgene's value of 50.40% is 302.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celgene's current EBITDA Margin % of 50.40% is 302.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Celgene and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celgene's current EBITDA Margin % is 50.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current EBITDA Margin % of 50.40%. The current EBITDA Margin % is 50.40% and 302.7% above the Drug Manufacturers industry median of 12.52. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Celgene (BUE:CELG), the current EBITDA Margin % is 50.40% as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celgene Business Description

Address 86 Morris Avenue, Summit, NJ, USA, 07901
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.